Karl‐Henrik Grinnemo

The paper performs single-cell proteomics on pancreatic islets from healthy and T1DM donors, identifying cell type-specific differences and donor-specific features.

This study improves clinical outcome predictions by integrating pharmacokinetic simulations into in vitro testing for colorectal cancer, showing better classification of responders and non-responders than traditional methods.

This study introduces SC-pSILAC, a method to measure protein abundance and turnover in single cells, revealing differentiation-specific dynamics and cell-type markers in human iPSCs.

This study improves single-cell proteomics by increasing protein identification from ~2000 to over 5000 per cell and enhancing throughput and reliability.